Zoetis (NYSE:ZTS) Given New $80.00 Price Target at Stifel Nicolaus

Zoetis (NYSE:ZTS) had its price objective cut by investment analysts at Stifel Nicolaus from $85.00 to $80.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has a “hold” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 4.19% from the company’s current price.

A number of other equities analysts have also weighed in on ZTS. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Piper Sandler cut their price target on Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a report on Monday, August 10th. TD Cowen reduced their price target on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Finally, Citigroup decreased their price objective on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. Eight equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis has an average rating of “Hold” and a consensus price target of $109.23.

Zoetis Trading Up 3.8%

Zoetis stock opened at $76.78 on Thursday. The stock has a market cap of $31.73 billion, a PE ratio of 12.65, a P/E/G ratio of 1.73 and a beta of 0.74. The stock has a 50-day moving average price of $75.92 and a 200 day moving average price of $97.81. Zoetis has a 52 week low of $71.00 and a 52 week high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities research analysts predict that Zoetis will post 6.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zoetis

Several institutional investors and hedge funds have recently bought and sold shares of ZTS. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Zoetis in the 2nd quarter valued at $25,000. Dunhill Financial LLC increased its holdings in shares of Zoetis by 519.3% during the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after buying an additional 296 shares during the last quarter. Prosperity Bancshares Inc purchased a new position in shares of Zoetis in the 4th quarter worth $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis in the 1st quarter worth $28,000. Finally, Root Financial Partners LLC boosted its holdings in Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.